AI Financial (AIFC) investor relations material

Executive summary

• Q3 continuing-operations revenue was $248k and gross profit was $88k; consolidated net loss was $18.2m, including a $9.5m loss from discontinued operations.

• 9M consolidated net loss was $519.2m, driven largely by a $637.2m noncash unrealized loss on WLFI tokens; period-end token fair value was $417.4m.

Financial highlights

• Q3 continuing revenue fell to $248k from $913k YoY; gross profit was $88k vs. $448k, and gross margin was 35.5% vs. 49.1%.

• 9M continuing revenue was $934k vs. $1.235m; gross profit rose to $546k from $446k, and gross margin increased to 58.5% from 36.1%.

• Continuing SG&A was $5.5m in Q3 and $10.7m for 9M, down from $12.6m and $15.1m, respectively, on the recast 2025 basis.

• Continuing operating loss was $5.436m in Q3 and $10.177m for 9M; consolidated net loss was $18.175m and $519.225m, respectively.

• Cash was $2.6m and a certificate of deposit was $1.3m at quarter-end; current assets of $7.3m and current liabilities of $20.9m resulted in a $13.6m working-capital deficit.

Outlook and guidance

• Discussions with two public companies contemplate a Drew transaction valuing the biotech assets at ~$200m; any deal remains subject to due diligence, definitive agreements and approvals, with no assurance of completion or valuation.

• Plans include pursuing WLFI staking revenue and continued use of eligible tokens as collateral; proceeds and timing depend on platform performance, lender availability and contractual restrictions.

• Additional debt or equity financing may be needed for acquisitions, Phase IIb biotech trials or other strategic investments, with potential dilution to existing holders.